Preserved Liver Transplant After PD-1 Pathway Inhibitor for Hepatocellular Carcinoma

Am J Gastroenterol. 2017 Dec;112(12):1895-1896. doi: 10.1038/ajg.2017.387.

Authors

Andreas Varkaris^{1

2

3}, David W Lewis⁴, Francis W Nugent⁵

Affiliations

¹ Department of General Internal Medicine, Lahey Clinic, Burlington, Massachusetts, USA.
² TUFTS Medical School, TUFTS University, Boston, Massachusetts, USA.
³ Alexandra General Hospital, National and Kapodistrian University of Athens, Athens, Greece.
⁴ Hepatobiliary Surgery and Liver Transplantation, Lahey Medical Center, Burlington, Massachusetts, USA.
⁵ Department of Oncology, Lahey Clinic, Burlington, Massachusetts, USA.

PMID: 29215617
DOI: 10.1038/ajg.2017.387

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Aged
Antibodies, Monoclonal, Humanized / therapeutic use*
Antineoplastic Agents, Immunological / therapeutic use*
Carcinoma, Hepatocellular / secondary
Carcinoma, Hepatocellular / therapy*
Fatal Outcome
Humans
Liver Neoplasms / pathology
Liver Neoplasms / therapy*
Liver Transplantation*
Lymphatic Metastasis
Male
Neoplasm Recurrence, Local / pathology
Neoplasm Recurrence, Local / therapy*
Programmed Cell Death 1 Receptor / antagonists & inhibitors

Substances

Antibodies, Monoclonal, Humanized
Antineoplastic Agents, Immunological
Programmed Cell Death 1 Receptor
pembrolizumab